Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR059 in Chinese Subjects With Type 2 Diabetes Mellitus
NCT07347080Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Primary endpoint: Treatment-Emergent Adverse Events. Started Jan 2026; status: recruiting.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07347080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347080.